Market whims and whispers can (and often do!) send shares in biotech stocks surging or plummeting, but managing volatility isn't the only challenge facing biotech investors. Biotech investors also ...

The DCF model is powerful but highly sensitive to key inputs: discount rate, perpetual growth rate, and growth assumptions. Choosing the right discount rate is crucial; too low or too high a rate can ...

Deteriorating Harvoni sales continue to push Gilead's valuation down, which presents an attractive entry point to buy the stock. Based on a conservative two-stage DCF model, I calculated 44% upside ...

If you are wondering whether Globus Medical is priced attractively today, you are not alone. The key is to look past the headline share price to what you are actually paying for the business. The ...

With no specific news catalyst flagged, CropEnergies (HMSE:CE2) still draws attention as investors weigh its recent share price moves and current €13.65 level against its calculated intrinsic discount ...

For more than half a decade weAAAve been managing money and writing articles as weAAAve always done. My discounted cash flow model's a bit different than most. If youAAAve ever taken a finance class ...

This article ( original research paper) proposes a systematic regression-based fundamental equity valuation model that can potentially be applied in areas such as quantitative finance and machine ...

In an appraisal proceeding under Section 262 of the Delaware General Corporation Law, the Delaware Court of Chancery determines the "fair value" of a company's "shares exclusive of any element arising ...

If you are wondering whether Denison Mines at around C$4.60 is offering good value or asking too much, you are not alone in trying to make sense of the current price. The stock has seen sharp moves ...

If you are wondering whether Altria Group's share price reflects its true worth today, you are not alone and this article is written with that exact question in mind. Altria Group recently closed at ...